HSO-001

HSO-001

HSO-001 synergistically lowered antibody levels, a measure of efficacy against hay fever. Based on these results, HSO-001 is expected to produce faster and longer-lasting effects.

HSO-001 is a novel and potent agonist for TLR4 (Toll-like receptor 4), which plays an important role in the recognition of allergens and the induction of immune responses, and is used in combination with existing sublingual immunotherapy drugs such as house dust (mites), birch pollen, and other tree and legume pollen. When used in combination with HSO-001 and the allergen (i.e., the sublingual immunotherapy drug), in mouse studies, it induced a 7-fold increase in allergen-specific IgG and IgA levels in the sublingual immune cells, which is a biomarker of efficacy, and this enhancement effect was observed in various allergens. Furthermore, data have also been obtained suggesting that HSO-001 increases the uptake of allergens by the immune cells in the sublingual region, involves Tregs, and inhibits histamine release in obese cells. Based on these findings, we believe that in clinical settings, the enhancement of the therapeutic effect and shortening of the treatment period of sublingual immunotherapy can be expected through these effects. Furthermore, data have also been obtained indicating that in atopic dermatitis and asthma, allergen immunotherapy is effective in reducing the severity of these allergic diseases. We are considering its application in these allergic diseases in 2027 when conducting Phase 1 trials and confirming safety and early POC. HISHOH has also signed a licensing agreement with Daiichi Sankyo Co., Ltd. in 2021, obtaining the right to conduct HSO-001 and is advancing the development of allergen immunotherapy.